Jan 31 (Reuters) - Moderna Inc said on Monday it received full approval from the U.S. Food and Drug Administration (FDA) for its COVID-19 vaccine for individuals 18 years of age and older. (Reporting by Amruta Khandekar; Editing by Anil D'Silva)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
124.1 USD | -0.87% | +5.63% | +24.74% |
07-17 | EU court criticizes Commission over handling of COVID vaccine contracts | RE |
07-15 | Moderna Insider Sold Shares Worth $1,756,177, According to a Recent SEC Filing | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.74% | 47.54B | |
-0.47% | 41.96B | |
+47.58% | 41.55B | |
+25.40% | 30.36B | |
+17.96% | 27.61B | |
-4.47% | 28.7B | |
+50.73% | 14.7B | |
+42.56% | 13.51B | |
+1.46% | 12.34B | |
-5.60% | 11.49B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- Moderna receives full U.S. approval for COVID-19 vaccine